Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.
Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.
The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.
Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.
Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.
Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.
Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.
Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.
Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.
Adam M. Brufsky, MD, PhD, discusses treatment options for male patients with breast cancer.
Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.
Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the potential for radiation combinations.
Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).
Telehealth, a universal term for the use of digital information and communication technologies to remotely access healthcare services, is improving availability of healthcare services, particularly for patients in rural areas.
Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade
Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.
Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.
Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.